Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Role of β-Blockers in Chronic Coronary Artery Disease Management in the Percutaneous Coronary Intervention Era: Good Symptom Control or Something More?

  • Ji Woong Roh (Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital) ;
  • Yongcheol Kim (Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital)
  • Received : 2022.04.13
  • Accepted : 2022.04.26
  • Published : 2022.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
  2. Puymirat E, Riant E, Aissaoui N, et al. β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ 2016;354:i4801.
  3. Greenberg B. Medical management of patients with heart failure and reduced ejection fraction. Korean Circ J 2022;52:173-97.
  4. Won H, Suh Y, Kim GS, Ko YG, Hong MK. Clinical impact of beta blockers in patients with myocardial infarction from the Korean National Health Insurance database. Korean Circ J 2020;50:499-508.
  5. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407-77.
  6. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019;40:87-165.
  7. Ozasa N, Morimoto T, Bao B, et al. β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure. Int J Cardiol 2013;168:774-9.
  8. Motivala AA, Parikh V, Roe M, et al. Predictors, trends, and outcomes (among older patients ≥65 years of age) associated with beta-blocker use in patients with stable angina undergoing elective percutaneous coronary intervention: insights from the NCDR registry. JACC Cardiovasc Interv 2016;9:1639-48.
  9. Park J, Han JK, Kang J, et al. The clinical impact of β-blocker therapy on patients with chronic coronary artery disease after percutaneous coronary intervention. Korean Circ J 2022;52:544-55.
  10. Ferrari R, Camici PG, Crea F, et al. Expert consensus document: a 'diamond' approach to personalized treatment of angina. Nat Rev Cardiol 2018;15:120-32.